En Es
Categories

Industry News

Quest Diagnostics Acquires Blueprint Genetics

By Labmedica International staff writers
30 Jan 2020

IllustrationQuest Diagnostics (Secaucus, NJ, USA), a provider of diagnostic information services, has acquired Blueprint Genetics (Helsinki, Finland), a specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development.

Founded in 2012, Blueprint Genetics’ growth is based largely on proprietary guideline-supported methods of gene variant interpretation of data generated from next generation sequencing, backed by high-touch consultative service. The company provides 3,900 targeted single gene and over 200 panel tests spanning 14 medical specialties. Gene variant interpretation involves identifying associations between gene variants and disease or treatment response.

Through its Advanced Diagnostics offerings, Quest specializes in combining state-of-the-art technologies, such as next generation sequencing, with higher-order interpretative expertise and digital customer enablement. Blueprint Genetics brings to Quest high-touch service in variant interpretation and reporting and associated sequencing and bioinformatics, which complement and extend its existing genetics leadership.

Blueprint Genetics has increased its focus and presence in the US through a recently established hub facility in Seattle, Washington. The acquisition provides a platform for Blueprint Genetics to leverage Quest's capabilities in next generation sequencing and national infrastructure serving half the health systems and physicians in the US. Blueprint Genetics is expected to continue to operate largely independently from its base laboratory in Helsinki, Finland, and a presence in other countries.

Over time, the acquisition is expected to yield new capabilities to serve providers specializing in rare disease and neurology, particularly pediatric and academic hospitals. The two organizations also envision that members of the Quest Diagnostics Global Diagnostic Network and its pharmaceutical and in vitro diagnostic collaborators will benefit from Blueprint Genetics' capabilities.

"The great challenge with genetic testing is generating quality, actionable and broadly accessible insights from vast quantities of sequenced genetic data," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. "Blueprint Genetics has developed a proven model for delivering highly specialized genetic insights that we believe we can scale to serve new patient populations with unmet clinical needs. The addition of Blueprint Genetics strengthens and extends the Quest value proposition in genetics, delivering on our Accelerate growth strategy and vision of a healthier world."

"As the leader in Advanced Diagnostics, Quest Diagnostics understands that robust bioinformatics and consultative expertise are essential to fast, accurate and cost-efficient data interpretation," said Carrie Eglinton Manner, Senior Vice President, Advanced Diagnostics, Quest Diagnostics. "Blueprint Genetics brings to Quest a proven platform in specialty genetics -- especially gene variant interpretation and reporting -- that powerfully differentiates our Advanced Diagnostics offering."

Related Links:
Quest Diagnostics
Blueprint Genetics




E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

23 Mar 2020
Artificial Intelligence-Based Methods to Cut MRI Read Times Receives USD 250K Grant
 Research to detect and predict blocked arteries and cardiovascular risk using knee MRI images conducted by Chun Yuan, Ph.D., Professor of Radiology and Bioengineering and Vice Chair for Global Affairs at the University of Washington (Seattle, WA, USA) has been recognized and awarded a grant by the American Heart Association’s (AHA) Institute for Precision Cardiovascular Medicine (Dallas, TX, USA).
Read More
23 Mar 2020
Surgical Robots Market to Reach USD 13.1 Billion by 2027 Due to High Acceptance in Emerging Regions
 The global surgical robots market is forecasted to reach USD 13.1 billion by 2027, driven mainly by low turn-around times and increased innovation in robotics over the coming years. Surgical robots are finding increased acceptance in the emerging Asia region, according to a study by Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider. The study is based on recent findings by IEEE (an Association for Electronic Engineering) that millennial parents are increasingly opting for robotic surgeries for their children in Asia Pacific region. The study also reveals that low availability of robotic surgeries remains a concern.
Read More
19 Mar 2020
Advantech Launches Medical-Grade AVAS-400 Series 4K UHD Video Recorder
 Advantech Co., Ltd. (Taipei, Taiwan), a provider of medical computing platforms and solutions, has launched its AVAS-400 Series medical-grade 4K ultra high-definition (UHD) video recorder aimed at ensuring operating precision. Advantech’s AVAS-400 Series, which includes two models, the AVAS-401 and the AVAS-402, are ideal for surgery centers, operating rooms, and training facilities that use 4K UHD cameras and display monitors for surgical operations and post-surgery reviews and research.
Read More
19 Mar 2020
Artificial Intelligence Helps Cancer Patients Start Radiation Therapy Sooner
 A new study by researchers from UT Southwestern’s Medical Artificial Intelligence and Automation (MAIA) Lab (Dallas, TX, USA) has demonstrated that artificial intelligence (AI) can help cancer patients start their radiation therapy sooner – and thereby decrease the odds of the cancer spreading – by instantly translating complex clinical data into an optimal plan of attack.
Read More
18 Mar 2020
Global Radiation Therapy Market to Reach USD 8.6 Billion by 2026 on Back of Product Approvals
 The global radiation therapy market is projected to record a steady growth rate of 5.2% from 2018 to 2026 to reach USD 8.6 billion by 2026, driven by a surge in product approvals, increased expenditure on healthcare, high incidence of cancer, growing preference for non-invasive treatment procedures, technological advancements, and notable research and development activities.
Read More
18 Mar 2020
Global Multiparameter Patient Monitoring Devices Market to Reach USD 6 Billion by 2025
 The global multiparameter patient monitoring devices market is expected to grow at a CAGR of over 4%, or record an incremental growth of around USD 1.32 billion, during the forecast period 2019?2025 to reach USD 6 billion in 2025. These are the latest findings of Arizton (Chicago, IL, USA), a provider of market research solutions.
Read More
17 Mar 2020
AI-based Ultrasound Echo Imaging Software Receives FDA Marketing Authorization
 The US Food and Drug Administration (FDA) has authorized the marketing of a software that uses artificial intelligence (AI) to assist medical professionals in the acquisition of cardiac ultrasound images. The software, Caption Guidance from Caption Health (Brisbane, CA, USA), a medical AI company, uses AI to empower medical professionals without specialized training to perform cardiac ultrasound.
Read More
17 Mar 2020
Global Defibrillators Market Projected to Reach USD 11.7 Billion by 2025
 The global defibrillators market is projected to grow at a CAGR of 3.4% from USD 9.6 billion in 2019 to USD 11.7 billion by 2025, driven by the rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training and awareness programs on defibrillators. Additionally, the emerging markets and the development of S-ICDs and MRI-compatible ICDs and CRT-Ds are expected to offer growth opportunities for the players in the defibrillators market. However, issues related to the use of implantable and automated external defibrillators, frequent product recalls, and lack of awareness about sudden cardiac arrest in the developing countries are expected to hinder the growth of the market during the forecast period.
Read More
16 Mar 2020
Global Blood Glucose Monitoring Devices Market to Reach USD 13 Billion by 2023
 The global blood glucose monitoring devices (BGMDs) market was valued at nearly USD 8 billion in 2018 and is projected to grow at a fast-paced CAGR of approximately 11% to reach USD 13 billion by 2023, driven by the phenomenal sales growth of new revolutionary continuous glucose monitoring systems (CGMs). However, the growth of CGMs will be offset by a steady decline in the blood glucose meters (BGMs) segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions